Earlier HCT before MDS or AML develops may improve survival in high-risk patients with Shwachman-Diamond syndrome.

More than 90% of children born with the rare bone marrow condition Shwachman-Diamond syndrome (SDS) survive beyond age 20.

Median duration of Complete Remission (CR) in treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) extended to 16.1 months with bexmarilimab + azacitidine Frontline HR-MDS treatment achieved ...

Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group Phase II Trial of First-Line Irinotecan in Patients With Advanced or Recurrent Squamous Cell ...

In MDS, don't just look at red blood cellsOne condition to be particularly aware of in elderly patients with macrocytic anemia is **myelodysplastic syndrome (MDS)**. In MDS, abnormalities occur in the ...

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, ...

Myelodysplastic syndromes (MDS) are treated based on type and risk assessment, but traditional therapies may not work for everyone. Clinical trials offer a way to explore emerging treatments and ...

Myelodysplastic syndromes (MDS) are blood cancers where bone marrow makes atypical red cells, white cells, or platelets. These cells may die early or not work well. Less aggressive MDS may still allow ...

Inherited bone marrow failure syndrome, or IBMFS, describes a group of disorders in which inherited genetic abnormalities impair the bone marrow's ability to produce sufficient healthy blood cells.